Compare IONS & AEIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONS | AEIS |
|---|---|---|
| Founded | 1989 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.8B |
| IPO Year | 1996 | 1996 |
| Metric | IONS | AEIS |
|---|---|---|
| Price | $75.65 | $310.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | $85.91 | ★ $278.36 |
| AVG Volume (30 Days) | ★ 1.9M | 668.2K |
| Earning Date | 05-25-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.14% |
| EPS Growth | 21.71 | ★ 168.53 |
| EPS | N/A | ★ 3.84 |
| Revenue | N/A | ★ $453,095,000.00 |
| Revenue This Year | N/A | $21.75 |
| Revenue Next Year | $66.43 | $13.24 |
| P/E Ratio | ★ N/A | $75.78 |
| Revenue Growth | N/A | ★ 38.39 |
| 52 Week Low | $23.95 | $75.01 |
| 52 Week High | $86.74 | $350.00 |
| Indicator | IONS | AEIS |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 53.77 |
| Support Level | $75.66 | $196.68 |
| Resistance Level | $84.81 | $350.00 |
| Average True Range (ATR) | 2.77 | 14.98 |
| MACD | -0.88 | -5.72 |
| Stochastic Oscillator | 24.03 | 38.86 |
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.